Lay Summary: Allogeneic stem cell transplantation is standard of care for younger patients with MDS.
Allogeneic stem cell transplantation is standard of care for younger patients with MDS. Age 60 is considered appropriate for it. The guidelines recommend that all patients < 65 years should be assessed for fitness/eligibility for allogeneic SCT as soon as possible after diagnosis, as SCT outcome is improved if performed early. If eligible and a sibling donor is available, it is recommended that patients < 50 years are offered ablative allogeneic SCT (evidence grade B, level IIb) and patients > 50 < 65 years are considered for non-ablative allogeneic SCT, within clinical trials where available (evidence grade C, level IV). The kind of transplant had not been defined, but the filed has moved toward older ages for both of these types of transplant.
Until the mid 1990s few patients over 55 years were offered allogeneic HSCT63 due to higher NRM in older patients. As only about 25% of MDS patients are younger than 60 years, efforts have focused on reducing the elevated risk of NRM associated with older age by modifying conditioning regimens (as discussed above), supportive care and complication management. Recent successfully transplanted cohorts included patients with median ages of 55–60 years, with some patients older than 70 years.
Patients with no sibling donor, but with an unrelated donor should also be considered for ablative unrelated-donor SCT. Case series and retrospective analyses demonstrate similar disease-free and overall survival rates with myeloablative and non-myeloablative/reduced-intensity conditioning regimens. Two-, three-, and four-year overall survival rates are 33% versus 35%, 39% versus 33%, and 36% versus 27%, respectively, for individuals undergoing allogeneic HSCT with myeloablative or non-myeloablative/reduced-intensity therapy
NCCN 2015 on p.MD S-11 footnotes the high dose therapy recommendation with “Hematopoietic stem cell transplant (HSCT): Allogeneic-matched sibling including standard and reduced-intensity preparative approaches or MUD”.
Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55
nccn, myelodysplatic, 2019
L. Muffly, M.C. Pasquini, M. Martens, R. Brazauskas, X. Zhu, K. Adekola, et al.Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States Blood, 130 (2017), pp. 1156-1164
Luca Malcovati et al,Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013 Oct 24; 122(17): 2943–2964.
Majhail, Navneet S. et al.Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation , Volume 21 , Issue 11 , 1863 – 1869
Teresa Field and Claudio Anasetti. Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome Medit J Hemat Infect Dis 2010, 2(2)
Matthias Bartenstein and H. Joachim Deeg, Hematopoietic Stem Cell Transplantation for MDS. Hematol Oncol Clin North Am. 2010 Apr; 24(2): 407–422.